Report title: NeuralStem Biopharmaceuticals, Ltd. - Portfolio Company Report
from Thomson Financial Venture Economics
published May 16, 2009

Price $24.00 available for immediate download
Report Overview
 
About Thomson Financial Venture Econ...

Develops therapies for patients with head trauma and spinal cord disorders. The Company's technology grows human neurons from central nervous system stem cells taken from post-mortem fetuses. NeuralStem uses these cells to screen potential drugs and to discover new drugs to treat disorders of the brain and spinal cord, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, spinal cord injury and epilepsy. ; Develops therapies for patients with head trauma and spinal cord disorders.

Report Type: This research report shows venture capital financing information for this specific company.
Executives Listed: 1
Number of Investing Funds: 1
Free Sample: Click Here to Download
Format:
PDF Adobe Acrobat


Price: $24.00



  Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.